# US 7,465,445 B2 · Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,465,445 B2
- Document ID: US7465445B2
- Status: Granted
- Kind: B2
- Application number: 10/729,880
- Filed: 2003-12-05
- Published: 2004-11-18
- Granted: 2008-12-16
- Earliest claimed: 1999-08-30
- Assignees: Japan Tobacco Inc.
- Inventors: Katsunari Tezuka; Yoshihiro Watanabe; Ryo Abe
- Web page: https://patentgrep.com/patent/US7465445B2

## CPC

- A61K 38/1709: {from mammals}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of an antibody against a foreign antigen triggered by immunological sensitization by the antigen.

## Claims

### Claim 1

A method of preventing or treating graft versus host reaction in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) an antibody or a portion thereof that binds to human AILIM and inhibits proliferation of an AILIM-expressing cell or production of interferon-gamma or interleukin-4 by an AILIM-expressing cell, and (b) a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody or portion thereof is a monoclonal antibody.

### Claim 3 (depends on 2)

The method of claim 2, wherein the monoclonal antibody is a chimeric monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody or portion thereof is an F(ab′)2fragment, an Fab′ fragment, an Fab fragment, an Fv fragment, or a single domain antibody.